Anti-Mouse PD-1 [Clone RMP1-30] — Purified in vivo GOLD™ Functional Grade
Anti-Mouse PD-1 [Clone RMP1-30] — Purified in vivo GOLD™ Functional Grade
Product No.: C3442
Clone RMP1-30 Target PD-1 Formats AvailableView All Product Type Monoclonal Antibody Alternate Names Programmed Death-1, CD279 Isotype Rat IgG2b κ Applications Depletion , FC , in vivo |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Rat Recommended Isotype Controls Recommended Dilution Buffer Immunogen Mouse PD-1 transfected BHK cells Product Concentration ≥ 5.0 mg/ml Endotoxin Level <1.0 EU/µg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C Applications and Recommended Usage? Quality Tested by Leinco FC IHC FF Additional Applications Reported In Literature ? FC Depletion Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity RMP1-30 activity is directed against mouse PD-1 (CD279).
Background PD-1, a member of the CD28/CTLA-4 subfamily of the Ig superfamily, is a transmembrane protein expressed on activated T cells, B cells, a subset of thymocytes, macrophages, dendritic cells, and some tumor cells1,2. PD-1 is also retained in the intracellular compartments of human and mouse regulatory T cells (Tregs) and is co-expressed with CD25 on activated CD4+ T cells3. When stimulated via the T cell receptor (TCR), Tregs translocate PD-1 to the cell surface3. PD-1 is absent on naïve T cells and is inducibly expressed on T cells by T cell antigen receptor (TCR). B7-H1 (PD-L1; CD274) and B7-DC (PD-L2; CD273) have been identified as PD-1 ligands1. PD-1 is co-expressed with PD-L1 on tumor cells and tumor-infiltrating antigen-presenting cells (APCs)2.
PD-1 acts as a T cell inhibitory receptor and plays a critical role in peripheral tolerance induction and autoimmune disease prevention as well as important roles in the survival of dendritic cells, macrophage phagocytosis, and tumor cell glycolysis2. PD-1 prevents uncontrolled T cell activity, leading to attenuation of T cell proliferation, cytokine production, and cytolytic activities. Additionally, the PD-1 pathway, consisting of PD-1 on T cells and PD-L1 on APCs, is a major mechanism of tumor immune evasion, and, as such, PD-1 is a target of cancer immunotherapy2. RMP1-30 does not block the binding of B7-H1 or B7-DC to PD-11. However, recent studies show that RMP1-30 does deplete PD-1 expressing cells 28. Antigen Distribution PD-1 is expressed on activated T cells, B cells, a subset of thymocytes, macrophages, dendritic cells, and some tumor cells.
NCBI Gene Bank ID Research Area Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone RMP1-30 is a rat monoclonal antibody specific for mouse PD-1 (CD279), and its common in vivo applications in mice are primarily for detection and characterization of PD-1 expression, such as via flow cytometry and immunophenotyping, rather than for functional blocking of PD-1 signaling. Key in vivo uses of RMP1-30 in mice include:
Limitations and Important Notes:
Summary Table: RMP1-30 in Vivo Applications in Mice
When planning experiments requiring functional modulation (blockade or agonism) of mouse PD-1 signaling in vivo, alternative clones should be selected. RMP1-30 is commonly used in combination with several other antibodies and proteins in murine immune checkpoint research, particularly for validation, epitope mapping, and functional studies. Anti-PD-1 Antibodies29F.1A12 is one of the most frequently paired antibodies with RMP1-30. These two clones recognize overlapping populations, with co-staining studies showing that approximately 90-97% of PD-1-positive cells are dual positive for both antibodies. The 29F.1A12 antibody is particularly notable because it functions as a strong blocking antibody that can prevent PD-1/PD-L1 interactions, whereas RMP1-30 cannot block this interaction. This complementary functionality makes them useful together in experimental designs where one antibody blocks immune checkpoint signaling while the other serves as a detection reagent. RMP1-14 is another anti-PD-1 antibody frequently used alongside RMP1-30. Like 29F.1A12, RMP1-14 has blocking capability, though it requires approximately 100-fold higher concentrations to achieve similar effects. RMP1-30 can be used to stain for PD-1 in experiments where RMP1-14 is employed therapeutically, though with an approximately 25% decrease in fluorescence when the therapeutic antibody is already bound to PD-1. PD-L1 and Checkpoint ProteinsPD-L1 (also known as B7-H1) is frequently investigated in the same experimental systems as RMP1-30. As the primary ligand for PD-1, PD-L1 antibodies such as clone 10F.9G2 are often used in combination studies to understand the complete checkpoint interaction pathway. Additionally, PD-L2, the second ligand for PD-1, is relevant in these studies as it can also mediate inhibitory signals through PD-1 binding. These antibody combinations are critical for dissecting immune checkpoint roles in health and disease, with researchers often using RMP1-30 for detection purposes while employing blocking antibodies like 29F.1A12 to modulate immune responses therapeutically. Clone RMP1-30 is a monoclonal antibody against mouse PD-1 that has been widely cited in the scientific literature primarily as a PD-1 detection reagent in flow cytometry and immunophenotyping applications, but it does not function as a blocking antibody for the PD-1/PD-L1 interaction. Key findings from scientific literature citations of RMP1-30:
Additional notes:
In summary, RMP1-30 is a reliable, non-blocking anti–PD-1 clone for detection and phenotyping of murine PD-1, frequently used in combination antibody panels to dissect immune cell and tumor PD-1 expression, but is not used for functional PD-1 blockade in immunotherapy research. Dosing regimens for clone RMP1-30 (anti-mouse PD-1 antibody) vary substantially across mouse models and research applications, with no single standardized protocol universally adopted. Most commonly, RMP1-30 is used for flow cytometry and immunophenotyping, not in vivo functional blockade; dosing and scheduling are therefore tied to experimental goals, cell numbers, and application type. Key context for RMP1-30 dosing:
Dosing Regimen VariationFor flow cytometry:
For in vivo use:
Essential Points
If your application is functional PD-1 blockade (e.g., immunotherapy or checkpoint studies), RMP1-30 is not appropriate due to its lack of blocking activity—use clones such as 29F.1A12 or RMP1-14 for those protocols. In summary, doses of RMP1-30 are not standardized and vary with the mouse model and experimental objective, most commonly employed for PD-1 detection rather than in vivo modulation. References & Citations1. Matsumoto K, Inoue H, Nakano T, et al. J Immunol. 172(4):2530-2541. 2004.
2. Zhao Y, Harrison DL, Song Y, et al. Cell Rep. 24(2):379-390.e6. 2018. 3. Raimondi G, Shufesky WJ, Tokita D, et al. J Immunol. 176(5):2808-2816. 2006. 4. Ding ZC, Habtetsion T, Cao Y, et al. Sci Rep. 7(1):12168. 2017. 5. Chatterjee S, Daenthanasanmak A, Chakraborty P, et al. Cell Metab. 27(1):85-100.e8. 2018. 6. Snell LM, MacLeod BL, Law JC, et al. Immunity. 49(4):678-694.e5. 2018. 7. Bradley CP, Teng F, Felix KM, et al. Cell Host Microbe. 22(5):697-704.e4. 2017. 8. Uchil PD, Pi R, Haugh KA, et al. Cell Host Microbe. 25(1):87-100.e10. 2019. 9. Timilshina M, You Z, Lacher SM, et al. Cell Rep. 27(10):2948-2961.e7. 2019. 10. Chow MT, Ozga AJ, Servis RL, et al. Immunity. 50(6):1498-1512.e5. 2019. 11. St Clair JB, Detanico T, Aviszus K, et al. PLoS One.12(1):e0170556. 2017. 12. Liu QZ, Ma WT, Yang JB, et al. Front Immunol. 9:1090. 2018. 13. Vanderleyden I, Fra-Bido SC, Innocentin S, et al. Cell Rep. 30(3): 611–619.e4. 2020. 14. Bally AP, Tang Y, Lee JT, et al. J Immunol. 198(1):205–217. 2017. 15. Quatrini L, Wieduwild E, Escaliere B, et al. Nat Immunol. 19(9):954-962. 2018. 16. Shimizu K, Sugiura D, Okazaki IM, et al. Mol Cell. 77(5):937-950.e6. 2020. 17. Karnowski A, Chevrier S, Belz GT, et al. J Exp Med. 209(11):2049-2064. 2012. 18. Park HJ, Kusnadi A, Lee EJ, et al. Cell Immunol. 278(1-2):76-83. 2012. 19. Huang JR, Tsai YC, Chang YJ, et al. J Immunol. 192(4):1972-1981. 2014. 20. Park SJ, Namkoong H, Doh J, et al. J Leukoc Biol. 96(5):939. 2014. 21. Puleston DJ, Zhang H, Powell TJ, et al. Elife. 3:e03706. 2014. 22. Lu X, Ding ZC, Cao Y, et al. J Immunol. 194(4):2011-2021. 2015. 23. Bally AP, Lu P, Tang Y, et al. J Immunol. 194(9):4545-4554. 2015. 24. Zeng, W., Liu, Z., Zhang, S. et al. Sci Rep. 6:36560. 2016. 25. Zhuang Z, Lai X, Sun J, et al. J Exp Med. 218(4):e20202187. 2021. 26. Mitchell JE, Lund MM, Starmer J, et al. Cell Rep. 35(2):108966. 2021. 27. Christian LS, Wang L, Lim B, et al. Cell Rep. 35(6):109118. 2021. 28. Cui J, Xu H, Yu J, Ran S, Zhang X, et al. Sci Immunol. 9(94):eadh0085. 2024. Technical ProtocolsCertificate of Analysis |
Related Products
Formats Available
Prod No. | Description |
---|---|
C3444 | |
C3452 | |
C3441 | |
C3446 | |
C3450 | |
C3442 | |
C3448 | |
P415 |
